Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES IZETTLE AB IN CONNECTION WITH CAPITAL RAISING
Mandate

VINGE ADVISES IZETTLE AB IN CONNECTION WITH CAPITAL RAISING

May 14, 2014

iZettle AB has carried out a directed new issue of approximately EUR 40 million to the private equity companies Zouk Capital, Dawn Capital and Intel Capital as well as to some of the company’s existing shareholders in order to develop its payment services solutions and continue its expansion within and outside Sweden.

iZettle AB makes it possible for businesses and private persons to receive card payments by downloading iZettle AB’s app to an iPhone or iPad (with or without a card reader).

Vinge’s team consisted of responsible partner Henrik Wenckert together with, among others, associates Malin Buch and Filip Brosset.  

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024